Journal issues > Issue 1, February 2025 > Highlights in acute lymphoblastic leukaemia

Highlights in acute lymphoblastic leukaemia

SUMMARY

In previous ASH meetings, the focus has long been on novel drugs for R/R ALL such as blinatumomab, inotuzumab, and CAR-T. Today, we have exciting information on how the incorporation/combination of these novel agents in the first-line treatment of ALL patients (pts) could reduce the incidence of relapse and prolong the survival of these pts, thus challenging the indication of hematopoietic stem cell transplantation (HSCT) in first complete remission (CR).

(BELG J HEMATOL 2025;16(1):31–3)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top